D011728Chemicals & DrugsD03.383.725.79138510.960436Pyridonesplugins:TwitterTwitterprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonBiochemistry and Molecular Biology32449254Salvatore M, Laplante JM, Soave R, Orfali N, Plate M, van Besien K, St George KTransplant infectious disease : an official journal of the Transplantation SocietyBaloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020 Aug; 22(4):e13336.Transpl Infect Dis2020-06-10T00:00:002020Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.AyodejiAdegunsoyeAyodeji Adegunsoye41.7886000000000087.598699999999993924Adegunsoye, AyodejiAssistant Professor32969288Tafur AJ, Clark NP, Spyropoulos AC, Li N, Kaplovitch E, MacDougall K, Schulman S, Caprini JA, Douketis JJournal of the American Heart AssociationPredictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. J Am Heart Assoc. 2020 10 20; 9(19):e017316.J Am Heart Assoc2020-09-24T00:00:002020Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study.Medicine-Hematology and OncologyMedicine-Pulmonary and Critical Care34633405Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan BA, Eng H, Martin D, Zaharris E, Everett B, Castro L, Shapiro NL, Lin JY, Hou PC, Pepine CJ, Handberg E, Haight DO, Wilson JW, Majercik S, Fu Z, Zhong Y, Venugopal V, Beach S, Wisniewski S, Ridker PM, ACTIV-4B InvestigatorsJAMAEffect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. 2021 11 02; 326(17):1703-1712.JAMA2021-11-02T00:00:002021Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.35738590Albert DH, Goodwin NC, Davies AM, Rowe J, Feuer G, Boyiadzis M, Dorritie KA, Mancini M, Gandour-Edwards R, Jonas BA, Borthakur G, Aldoss I, Rizzieri DA, Odenike O, Prebet T, Singh S, Popovic R, Shen YU, McDaniel KF, Kati WM, Modi DA, Motwani M, Wolff JE, Frost DJIn vivo (Athens, Greece)Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo. 2022 Jul-Aug; 36(4):1615-1627.In Vivo2022-07-01T00:00:002022Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.drdayjee1.301450.015103938research area of0.8863030.018922546subject area forMedicineUniversity of ChicagoJoseph A.Piccirilli3XJgCKIcC+X5hHlsaUXv9Gq0+s+oJoseph A. Piccirilli41.78927490000000-87.60125000000000190Piccirilli, Joseph A.ProfessorJerroldLeikinJerrold Leikin41.78927490000000-87.601250000000002380Leikin, JerroldClinical ProfessorMary ElizabethStrekMary Elizabeth Strek41.78927490000000-87.601250000000002563Strek, Mary ElizabethProfessorOlatoyosiOdenikew21tDq8cEun5hHlsaUXv9Gq0+s+oOlatoyosi Odenike41.78927490000000-87.60125000000000399Odenike, OlatoyosiProfessor32453591Li Y, Zhao J, Gutgesell LM, Shen Z, Ratia K, Dye K, Dubrovskyi O, Zhao H, Huang F, Tonetti DA, Thatcher GRJ, Xiong RJournal of medicinal chemistryNovel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. J Med Chem. 2020 07 09; 63(13):7186-7210.J Med Chem2020-06-15T00:00:002020Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.true1ProfessorProfessortrue1Clinical ProfessorClinical Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessor